- Our Services
-
Patients and Families
- Get Directions
- Parking
- Childrens Locations
- Getting Around
- Guidelines for Visitors
- Contact a Patient
- Contact Children's
- Send an e-Card
- Gift Shop
Planning a Visit
- Find a Doctor
- Child Health A-Z
- Community Ed.Classes
- Injury Prevention
- International Patients
- Medical Records
- Patient Handbook
- Patient Procedures
Parents
- For Health Professionals
- Research
- Ways to Give
-
News
-
Adding Breast Milk Ingredient to Formula Could Prevent Deadly Intestinal Problem in Premature Babies
-
Children's Holds Groundbreaking Ceremony for Expansion to New South Fayette Location
-
Child Neurodevelopmental and Mental Health Disabilities on the Rise, Study Finds
News Releases
-
Research
APRIL-OCELOT Study for Coughing/Wheezing Preschoolers – Phase III
Azithromycin for Preventing Development of Upper Respiratory Tract Illness into Lower Respiratory Tract Symptoms (APRIL) and Oral Corticosteroids for Treating Episodes of Significant LOwer respiratory Tract Symptoms in Children (OCELOT)
Protocol Description
The purpose of this multicenter research, which is being conducted through AsthmaNet, is to study two treatment plans that address severe bouts of coughing and/or wheezing in preschool aged children. One treatment plan, known as APRIL, will try to prevent bad coughing or wheezing by using the oral antibiotic azithromycin when early signs of respiratory illness (or a cold), are observed. The second treatment plan, OCELOT, will evaluate whether the oral corticosteroid prednisolone is effective at decreasing symptoms if an illness develops during APRIL treatment. AsthmaNet is a nationwide clinical research network created by the National Heart Lung and Blood Institute.
Study Level: Phase III
Eligibility Criteria
Subject to certain exclusions, this study is open to children of both genders, from ages 1 through 5, who are having repeated wheezing episodes, and who may also suffer from asthma.
Males: Ages 1 through 5 years (71 months)
Females: Ages 1 through 5 years (71 months)
Requirements
Participants will be registered in the AsthmaNet Registry, and then evaluated for 14 to 28 days to determine if they qualify for the study, during which time parents will need to keep a daily diary of their participating child’s breathing symptoms. Qualifying participants will then be assigned to the APRIL study, with half randomly selected to take the study drug azithromycin, and half taking a placebo. Participants who develop significant lower respiratory tract symptoms during APRIL may be assigned to the OCELOT portion of the study. OCELOT randomly determines the prescription of either the OCELOT study drug prednisolone or a placebo, and evaluates results using the Pediatric Respiratory Assessment Measure. Physical examinations will be required at certain intervals, and parents are required to closely coordinate with the research team regarding changes in their child’s health. AsthmaNet’s nurse center also provides after-hours phone support.
Visits: Will vary based on individual experiences
Duration: About 1 year (56 weeks)
Status: Open to Enrollment
Source(s) of Support
National Heart, Lung and Blood Institute
National Institutes of Health
Additional Resources
Study Description at National Institutes of Health
AsthmaNet
Primary Investigator(s)
Fernando Holguin, MD
Contact Information
For information or to enroll, please contact:
Julianne Parente, BSN, RN
412-692-8929
Last Update
April 25, 2012
April 25, 2012
